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Abstract
Background: We characterized the twin epidemics of new and prevalent hepatitis C virus (HCV) infections in British
Columbia, Canada to inform prevention, care and treatment programs.
Methods: The BC Hepatitis Testers Cohort (BC-HTC) includes individuals tested for HCV, HIV or reported as a case
of HBV, HCV, HIV or active TB between 1990–2013 linked with data on their medical visits, hospitalizations, cancers,
prescription drugs and mortality. Prevalent infection was defined as being anti-HCV positive at first test. Those with
a negative test followed by a positive test were considered seroconverters or new infections.
Results: Of 1,132,855 individuals tested for HCV, 64,634 (5.8 %) were positive and an additional 3092 cases tested
positive elsewhere for a total of 67,726. Of 55,781 HCV positive individuals alive at the end of 2013, 7064 were
seroconverters while 48,717 had prevalent infection at diagnosis. The HCV positivity rate (11.2 %) was highest in
birth cohort 1945–1964 which declined over time. New infections were more likely to be male, 15–34 years of age
(born 1965-1984), HIV- or HBV-coinfected, socioeconomically disadvantaged, have problematic drug and alcohol use
and a mental health illness. The profile was similar for individuals with prevalent infection, except for lower odds of
HBV-coinfection, major mental health diagnoses and birth cohort >1975.
Conclusions: The HCV positivity rate is highest in birth cohort 1945–1964 which represents most prevalent
infections. New infections occur in younger birth cohorts who are commonly coinfected with HIV and/or HBV,
socioeconomically marginalized, and living with mental illness and addictions.
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Background
Hepatitis C virus (HCV) is a major global public
health problem. Worldwide, approximately 184 mil-
lion people are infected [1], and in Canada, 210,753–
461,517 (0.66 %-1.3 %) people are estimated to be
infected with HCV [2]. In British Columbia (BC), the an-
nual rate of newly identified HCV cases is about 50 %
higher than the national average [3]. Untreated HCV
infected individuals have a ~5-fold increased all-cause
and ~20-fold increased risk of liver-related mortality
[4]. While treatment reduces both morbidity and
mortality, only about 10 % of infected individuals
have been treated in BC [5]. Newer well-tolerated and
highly effective direct acting antiviral agents, with
cure rate approaching 95 %, are expected to provide
new opportunities to prevent progressive liver disease
[6, 7]. However, a large number of people are unaware
of their infection [2, 8]. Characterising individuals who
have been tested and who test positive can help identify
prevention, testing, care and treatment strategies and
programs to reach people most in need.
In most developed countries, the different HCV affected
populations can be defined from their risk characteristics
that can inform prevention, testing and treatment policies.
HCV affected individuals could be classified into two
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broad groups: prevalent and new infections. Prevalent
HCV infections represent infections acquired in the dis-
tant past and these individuals are usually not involved in
ongoing risk activities. New infections represent ongoing
transmission usually occurring in people with high risk
activities such as injection drug use. These two groups dif-
fer not only in terms of demographics and risk factors but
also have varying levels of onward transmission risk and
hence unique needs for engagement in prevention and
care. Characterization of these population groups
using testing patterns, co-occurrence of other infec-
tions (HIV, tuberculosis [TB], sexually transmitted in-
fections [STIs], hepatitis B [HBV]), and social risk
factors (addiction and mental illness) could inform
the design of prevention, testing and treatment pro-
grams tailored to the specific needs of these groups.
In this paper, we characterize twin epidemics of HCV
infection by describing characteristics and associated
factors of acute and prevalent infections using data
from the BC Hepatitis Testers Cohort (BC-HTC). We
further characterize the HCV disease burden by birth
cohorts and present positivity by birth cohort to in-
form birth cohort screening.
Methods
The cohort and study population
The BC Hepatitis Testers Cohort(BC-HTC) includes
all individuals tested for HCV or HIV at the BC Public
Health Laboratory or reported to public health as a
confirmed case of HCV, HBV, HIV/AIDS or active TB.
The cohort is linked with medical visits, hospitaliza-
tions, prescription drugs, cancers and deaths [9–13]
(Table 1). Details of the cohort creation, linkage and
characteristics of matched and unmatched individuals
have been reported previously [14]. The overall link-
age rate for HCV was >85 % and approached 90 %
after 2006.
BC-HTC participants with at least one HCV test (anti-
body, HCV RNA, or genotype) or HCV case report
contributed to the analysis from their first HCV test date
(beginning 1992) or report (beginning 1990) through
date of death or December 31, 2013, whichever was
earliest (Table 1). We excluded data which preceded a
participants’ birth date or occurred >7 days after the
death date. Antibody tests in infants <18 months in the
absence of HCV RNA testing were excluded as passive
maternal antibody could not be ruled out.
Table 1 Criteria and Data Sources for the BC Hepatitis Testers Cohort (BC-HTC) and current analysis
Criteria for Inclusion in BC-HTC
All individuals:
• tested at the centralized provincial laboratory for HCV or HIV OR
• reported in BC as a confirmed case of HCV OR
• reported in BC enhanced surveillance system as a confirmed case of HIV or AIDS (all reports) OR
• reported in BC as a confirmed case of HBV OR
• reported in BC as a confirmed case of active TB (latent cases excluded) OR
• included in BC Enhanced Strain Surveillance System (EHSSS) as an acute HBV or HCV case
All individuals meeting at least one the above criteria were linked internally across all their tests and case reports. Those
with a valid personal health number (PHN) were then sent for deterministic linkage with province-wide Cancer and Ministry
of Health (MoH) datasets
Provincial Communicable Disease Data Sources
• BC-PHL HIV laboratory testing datasets (tests: ELISA, Western blot, NAAT, p24, culture)
• BC-PHL HCV laboratory tests datasets (tests: antibody, HCV RNA, genotyping)
• HIV/AIDS Information System (HAISYS) (public health HIV/AIDS case reports)
• Integrated Public Health information System (iPHIS) (public health case reports of HCV, HBV, and TB)
• Enhanced Strain Surveillance System (EHSSS) (risk factor data on a subset of acute HCV and acute HBV cases)
Data Date Ranges:
HIV lab data: 1988–2013




Cancer and MoH Administrative Data Sources
• BC Cancer Registry (BCCR) (primary tumour registry, excludes metastatic cancers)
• Discharge Abstracts Dataset (DAD) (hospitalization records)
• Medical Services Plan (MSP) (physician diagnostic and billing data)
• PharmaCare/PharmaNet (Pharma) (prescription drug dispensations)







The final BC-HTC comprises all individuals successfully linked on PHN to the MoH Client Roster (a registry of all BC residents
enrolled in the publicly-funded universal healthcare system)
Eligibility for current analysis
• all subjects included in final, linked BC-HTC with at least one valid HCV test (antibody, HCV RNA, or genotype) (1992–2013)
or HCV case report (1990–2013)
• subjects were censored for analysis date of death or December 31, 2013, whichever came first
• excluded all data preceding subject’s recorded date of birth
• excluded all data occurring more than 7 days after subject’s recorded date of death
• excluded HCV antibody tests in infants less than 18 months in the absence of HCV RNA confirmatory testing
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Definitions
A HCV case was defined as an individual testing positive
for either HCV antibody or RNA or genotype or was
reported as a HCV case through the public health
reporting system [15]. We considered participants who
were HCV antibody positive at their first test on record
as having prevalent infection as, without a prior nega-
tive test, a seroconversion interval cannot be estab-
lished and, based on natural history, most will be
chronically infected. Those cases not found in labora-
tory data but reported by public health as confirmed
HCV were considered prevalent infections. Individuals
with a negative followed by a positive test were consid-
ered seroconverters or new infections. Individuals who
seroconverted within 24 months of the last negative
test were termed 24-month seroconverters, while those
who seroconverted after 24 months are >24-months
seroconverters. For surveillance purposes in BC, acute
HCV infection is defined as seroconversion within the
previous 12 months [15]. Since the characteristics of
12- and 24-month seroconverters were similar as pre-
sented in Additional file 1: Table S2, we report 0–24-
month seroconverters as acute HCV cases. Co-infection
was defined as being infected with HIV, HBV or active
TB together with HCV.
Socioeconomic status was assessed using the Québec
Index of Material and Social Deprivation, a widely used
index based on Canadian Census data [16]. Data from
each census, conducted every 5 years, was applied to
two years before and two years after the census year. For
the 2011 census, the index is based on the data product
CensusPlus to address non-response related bias in the
2011 National Household Survey [17].
Assessment of illicit drug use, mental illnesses, and
problematic alcohol use was based on having diag-
nostic codes in administrative health datasets evalu-
ated across all data prior to and within 3 years of
the first positive test or last negative test (Additional
file 1: Table S1).
Statistical analysis
We compared the characteristics of HCV positive cases
(24-month seroconverters, >24-month seroconverters
and prevalent cases) and negative groups using the chi-
square test for categorical factors or the Wilcoxon-
Mann-Whitney test for continuous variables. We calcu-
lated HCV positivity across birth cohorts and compared
their characteristics. Positivity rate is defined as number
of hepatitis C diagnoses divided by the total number of
people tested for hepatitis C. We performed multi-
nomial logistic regression to assess the factors associ-
ated with new and prevalent infections at diagnosis
compared to HCV negatives.
Results
Participant Profile, testing and infection prevalence
The cohort included 1,132,855 subjects tested for hepa-
titis C from 1992-2013. Of these, 64,634 (5.7 %) were
HCV positive. An additional 3092 cases tested elsewhere
and reported to the public health surveillance system
from 1990-2013 resulted in a total of 67,726 HCV cases.
Of HCV positive individuals, 11,945 (17.6 %) have died
and 55,781 were alive at the end of 2013. Among
1,068,221 HCV negative individuals, 79,840 (7.5 %) have
died and 988,381 were alive at the end of 2013. The fol-
lowing results are from individuals alive as of December
31, 2013 unless specified otherwise.
Characteristics of HCV positive and negative individuals
For HCV positive individuals, the median age at their first
test was 40 years and 35 years for HCV negative
individuals. A comparatively small proportion (12.2 %) of
HCV positive individuals were born after 1975 compared
to those HCV negative (37.6 %; p < 0.001). A higher propor-
tion of HCV positives compared to negatives were male
(64.4 % vs. 44.1 %; p < 0.001). Infection with HIV (5.7 % vs.
0.5 %; p < 0.001), HBV (3.7 % vs. 2.0 %; p < 0.001) and active
TB (0.5 % vs 0.2 %; p < 0.001) were significantly higher in
HCV positives than negatives. There was a graded in-
crease in percent HCV positivite with increases in mater-
ial (most privileged: 3.2 % vs. most deprived: 8.0 %) and
social deprivation (most privileged: 3.1 % vs. most de-
prived: 7.7 %). There were fewer privileged (material: 13.4
% vs. 22.0 %/social: 11.0 % vs 18.5 %) and more deprived
(material: 29.6 % vs. 18.8 %; p < 0.001/social: 37.7 % vs.
24.8 %; p < 0.001) individuals among HCV positives com-
pared to HCV negatives. The proportions with illicit drug
use (35.2 % vs. 7.0 %), problematic alcohol use (21.7 % vs.
6.2 %) and mental health conditions (16.0 % vs. 12.0 %) at
diagnosis were also higher among HCV positives com-
pared to HCV negatives (Table 2).
Seroconversion and characteristics of new and prevalent
HCV cases
Of 370,741 individuals who tested for anti-HCV multiple
times since 1992, 7726 (2.1 %) seroconverted. Among
the 346,428 currently alive repeat testers, 6922 (2.0 %)
seroconverted. Among those testing only once (n =
762,114), 56,908 (7.5 %) tested positive (prevalent HCV
infections). Of these, 695,137 were alive at the end of
2013 and 46,262 (6.7 %) were positive.
Of the 6922 currently alive seroconverters, 1989 (28.7 %)
seroconverted within 12 months, 1497 (21.6 %) in 12-24
months and 3436 (49.6 %) >24-months after their last nega-
tive test (Additional file 1: Table S2).
24-month seroconverters and reported acute cases
were younger than both >24-month seroconverters and
individuals with prevalent infection (median ages: 30, 35,
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Table 2 Characteristics of HCV positive and negative individuals, BC-HTC, Canada, 1990-2013
HCV + ve group HCV -ve group
M24 Seroa >M24 Serob Prevalent HCV All Positives All Negatives
N = 3628 N = 3436 N = 48717 N = 55781 N = 988381
N (%) N (%) N (%) N (%) N (%)
Age at baselinec
< 15 17 (0.5) 1 (0.0) 420 (0.9) 438 (0.8) 20289 (2.1)
15-24 962 (26.5) 410 (11.9) 2410 (5.0) 3782 (6.8) 145326 (14.7)
25-34 1477 (40.7) 1234 (35.9) 9907 (20.3) 12618 (22.6) 259347 (26.2)
35-44 827 (22.8) 1106 (32.2) 16534 (33.9) 18467 (33.1) 220626 (22.3)
45-54 275 (7.6) 522 (15.2) 13068 (26.8) 13865 (24.9) 163134 (16.5)
≥ 55 70 (1.9) 163 (4.7) 6378 (13.1) 6611 (11.9) 179659 (18.2)
Median [IQR] 30 [24-37] 35 [28-43] 42 [34-49] 41 [33-48] 37 [28-50]
Age at 1st test
< 15 100 (2.8) 84 (2.4) 421 (0.9) 605 (1.1) 25860 (2.6)
15-24 1485 (40.9) 1128 (32.8) 2422 (5.0) 5035 (9.0) 189747 (19.2)
25-34 1225 (33.8) 1278 (37.2) 9927 (20.4) 12430 (22.3) 261056 (26.4)
35-44 605 (16.7) 712 (20.7) 16590 (34.1) 17907 (32.1) 208398 (21.1)
45-54 169 (4.7) 195 (5.7) 13063 (26.8) 13427 (24.1) 147688 (14.9)
≥ 55 44 (1.2) 39 (1.1) 6294 (12.9) 6377 (11.4) 155632 (15.8)
Median [IQR] 26 [20-34] 28 [22-35] 42 [34-49] 40 [32-48] 35 [26-48]
Birth year
< 1945 31 (0.9) 35 (1.0) 3102 (6.4) 3168 (5.7) 95848 (9.7)
1945-1964 776 (21.4) 1037 (30.2) 32133 (66.0) 33946 (60.9) 310845 (31.5)
1965-1974 1176 (32.4) 1214 (35.3) 9493 (19.5) 11883 (21.3) 209956 (21.2)
≥ 1975 1645 (45.3) 1150 (33.5) 3989 (8.2) 6784 (12.2) 371732 (37.6)
Sex
Female 1728 (47.6) 1380 (40.2) 16741 (34.4) 19849 (35.6) 551952 (55.8)
Male 1900 (52.4) 2056 (59.8) 31970 (65.6) 35926 (64.4) 436287 (44.1)
Unknown 0 (0.0) 0 (0.0) 6 (0.0) 6 (0.0) 142 (0.0)
Year of diagnosis
1990-1994 85 (2.3) 4 (0.1) 3978 (8.2) 4067 (7.3) 3913 (0.4)
1995-1999 726 (20.0) 353 (10.3) 17936 (36.8) 19015 (34.1) 104863 (10.6)
2000-2004 1177 (32.4) 939 (27.3) 11733 (24.1) 13849 (24.8) 172888 (17.5)
2005-2009 994 (27.4) 1280 (37.3) 9130 (18.7) 11404 (20.4) 272886 (27.6)
2010-2013 646 (17.8) 860 (25.0) 5940 (12.2) 7446 (13.4) 433831 (43.9)
HIV/AIDS at baseline
Unknown 3450 (95.1) 3207 (93.3) 47568 (97.6) 54225 (97.2) 984182 (99.6)
Yes 178 (4.9) 229 (6.7) 1149 (2.4) 1556 (2.8) 4199 (0.4)
HIV/AIDS (ever)
Unknown 3264 (90.0) 3104 (90.3) 46257 (95.0) 52625 (94.3) 983694 (99.5)
Yes 364 (10.0) 332 (9.7) 2460 (5.0) 3156 (5.7) 4687 (0.5)
HBV at baseline
No/Unknown 3528 (97.2) 3349 (97.5) 48197 (98.9) 55074 (98.7) 974223 (98.6)
Yes 100 (2.8) 87 (2.5) 520 (1.1) 707 (1.3) 14158 (1.4)
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Table 2 Characteristics of HCV positive and negative individuals, BC-HTC, Canada, 1990-2013 (Continued)
HBV (ever)
No/Unknown 3453 (95.2) 3326 (96.8) 46927 (96.3) 53706 (96.3) 968459 (98.0)
Yes 175 (4.8) 110 (3.2) 1790 (3.7) 2075 (3.7) 19922 (2.0)
Active TB at baseline
No/Unknown 3621 (99.8) 3428 (99.8) 48634 (99.8) 55683 (99.8) 986909 (99.9)
Yes 7 (0.2) 8 (0.2) 83 (0.2) 98 (0.2) 1472 (0.1)
Active TB (ever)
No/Unknown 3611 (99.5) 3415 (99.4) 48466 (99.5) 55492 (99.5) 986473 (99.8)
Yes 17 (0.5) 21 (0.6) 251 (0.5) 289 (0.5) 1908 (0.2)
Material deprivation quintile at baseline
Unknown 96 (2.7) 79 (2.3) 2316 (4.8) 2491 (4.5) 14773 (1.5)
Q1 (most privileged) 452 (12.5) 444 (12.9) 6247 (12.8) 7143 (12.8) 214007 (21.7)
Q2 526 (14.5) 463 (13.5) 7500 (15.4) 8489 (15.2) 187587 (19)
Q3 531 (14.6) 585 (17.0) 8522 (17.5) 9638 (17.3) 192265 (19.5)
Q4 876 (24.2) 774 (22.5) 10580 (21.7) 12230 (21.9) 197116 (19.9)
Q5 (most deprived) 1147 (31.6) 1091 (31.8) 13552 (27.8) 15790 (28.3) 182633 (18.5)
Social deprivation quintile at baseline
Unknown 96 (2.7) 79 (2.3) 2316 (4.8) 2491 (4.5) 14773 (1.5)
Q1 (most privileged) 271 (7.5) 283 (8.2) 5302 (10.9) 5856 (10.5) 180214 (18.2)
Q2 349 (9.6) 337 (9.8) 6194 (12.7) 6880 (12.3) 175098 (17.7)
Q3 540 (14.9) 463 (13.5) 8094 (16.6) 9097 (16.3) 175715 (17.8)
Q4 703 (19.4) 720 (21.0) 9972 (20.5) 11395 (20.4) 201551 (20.4)
Q5 (most deprived) 1669 (46.0) 1554 (45.2) 16839 (34.6) 20062 (36) 241030 (24.4)
Mental health at baselined
No/Unknown 2199 (64.5) 2096 (65.0) 40934 (86.7) 45229 (84.0) 729398 (88.0)
Yes 1209 (35.5) 1130 (35.0) 6297 (13.3) 8636 (16.0) 99054 (12.0)
Mental health 3yrs pre-baselined
No/Unknown 2590 (76.0) 2653 (82.2) 43518 (92.1) 48761 (90.5) 781042 (94.3)
Yes 818 (24.0) 573 (17.8) 3713 (7.9) 5104 (9.5) 47410 (5.7)
Illicit drug use at baselined
No/Unknown 910 (26.7) 942 (29.2) 33036 (69.9) 34888 (64.8) 770499 (93.0)
Yes 2498 (73.3) 2284 (70.8) 14195 (30.1) 18977 (35.2) 57953 (7.0)
Illicit drug use 3yrs pre-baselined
No/Unknown 1084 (31.8) 1433 (44.4) 36193 (76.6) 38710 (71.9) 795325 (96.0)
Yes 2324 (68.2) 1793 (55.6) 11038 (23.4) 15155 (28.1) 33127 (4.0)
Problematic alcohol use at baselined
No/Unknown 2083 (61.1) 1896 (58.8) 38178 (80.8) 42157 (78.3) 777271 (93.8)
Yes 1325 (38.9) 1330 (41.2) 9053 (19.2) 11708 (21.7) 51181 (6.2)
Problematic alcohol use 3yrs pre-baselined
No/Unknown 2521 (74.0) 2555 (79.2) 41709 (88.3) 46785 (86.9) 802492 (96.9)
Yes 887 (26.0) 671 (20.8) 5522 (11.7) 7080 (13.1) 25960 (3.1)
a24-month Sero: Individuals who seroconverted within 24 months of the last negative test
bIndividuals who seroconverted after 24 months of the last negative test
cBaseline is defined as date of diagnosis (i.e. first HCV positive test or case report) for HCV positive individuals, and date of last negative test result for HCV
negative individuals
dMental health, drug misuse, alcohol misuse data was available up to 2012
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42 years; p < 0.001). Most of the individuals with preva-
lent infection (66.0 %) were born between 1945-64 with
another 19.5 % between 1965-74. Of 24-month serocon-
verters, 32.4 % were born in 1965-74, and 45.3 % after
1975. A higher percentage of prevalent cases and >24-
month seroconverters were male compared to 24-month
seroconverters (65.6 %, 59.8 % vs 52.4 %) (Table 2).
HIV and HBV co-infections were higher among 24-
month seroconverters compared to prevalent HCV cases
(HIV: 10.0 % vs. 5.1 %; HBV: 4.8 % vs. 3.7 %) while the
proportion with active TB was the same (0.5 % vs. 0.5 %)
(Fig. 1a). The proportions with illicit drug use (73.3 %
vs. 30.1 %), problem alcohol use (38.9 % vs. 19.2 %) and
mental health conditions (35.5 % vs. 13.3 %) were also
higher among 24-month seroconverters than individuals
with prevalent HCV infection (Table 2, Fig. 1b).
Characteristics of participants diagnosed in recent years
(2010-2013) are presented in Additional file 1: Table S3.
Overall characteristics are similar with differences in age
at diagnosis, birth cohort, HIV, HBV infection, and mental
illness mainly in 24 month seroconverters.
HCV infection by birth cohort
HCV positivity rates showed a strong birth cohort effect
(Fig. 2a, b Additional file 1: Figure S1). Birth cohorts
1950-1954 and 1955-59 had the highest percentage posi-
tive overall followed by 1960-64 though positivity declined
over time and was lowest in 2013. Birth cohorts 1945-49
a
b
Fig. 1 a Distribution of illicit drug use, alcohol use, and mental illness by HCV infection status in BC-HTC, Canada 1990-2013. b Distribution of co-infections
by HCV infection status in BC-HTC, Canada 1990-2013
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and 1965-69 had similar percentage positive though it was
slightly higher for 1945-49. In 2013, there were 1,262,121
people born between 1945 and 1964 living in BC; 344,791
(27.3 %) have been tested and 33,946 (9.8 %) were HCV
positive, of whom 7352 (17.8 %) have already died. As-
suming constant in and outflow, about 70 % of 1945-64
and 1950-70 birth cohorts have not been tested for HCV.
In birth cohort 1945-64, 67.8 % were male compared
to 63.9 % and 51.9 % of those born 1965-74 and after
1975, respectively. A small proportion (2.3 %) of 24-
month seroconverters was identified among HCV posi-
tives born 1945-64 compared to 9.9 % and 24.3 % among
1965-1974 and ≥1975 birth cohorts, respectively. In con-
trast, 97.9 %, 94.7 %, 79.9 % and 58.8 % HCV positive tests
a
b
Fig. 2 a Hepatitis C positivity by birth cohort in BC-HTC, British Columbia, Canada 1990-2013. HCV positives include both seroconverters and chronic
HCV. b Hepatitis C positivity by birth cohort and year in BC-HTC, British Columbia, Canada, 2001-2013
Janjua et al. BMC Infectious Diseases  (2016) 16:334 Page 7 of 14
were detected on the first test (prevalent infections)
among those born <1945, 1945-64, 1965-1974, and ≥1975,
respectively (Table 3).
The proportion of HCV/HIV co-infected individuals
increased with increasing birth year (<1945: 1.0 %, 1945-
64: 4.7 %, 1965-1974: 9.0 % and >1975: 6.6 %). In con-
trast, among HCV negative individuals, the HIV infec-
tion rates by birth cohort were higher among those
born between 1945-64 and 1965-74. HBV co-infection
was 2.9 %, 3.8 %, 4.7 % and 1.9 % among those born
<1945, 1945-64, 1965-1974, and ≥1975, respectively. Illicit
drug use (36.7 % vs 10.4 %), problematic alcohol use (22.3
% vs 11.7 %) and mental health conditions (16.4 % vs 10.2
%) were higher among those born after 1945 than those
born before 1945 (Table 3).
Factors associated with new and prevalent HCV infection
In the multivariable multinomial logistic regression
model (Table 4), new HCV infections were associated
with being male, born after 1945, HIV co-infection, HBV
co-infection, material deprivation, illicit drug use, prob-
lematic alcohol use and mental health diagnoses. The
same factors were associated with prevalent HCV infec-
tions except for lower odds for HBV co-infection, mental
health conditions and birth cohort ≥ 1975. The odds of
prevalent infection were highest in the 1945-54 birth
cohort (OR: 3.8, 95 % CI: 3.7-3.9) followed by 1955-64
(OR: 3.2, 95 % CI: 3.1-3.3), while the odds of being a new
infection were highest for the 1975-84 (OR: 11.8, 95 % CI:
9.9-14.1) birth cohort followed by those born 1965-74
(OR: 9.9, 95 % CI: 8.3-11.8). Furthermore, odds ratios for
illicit drug use (ORs: 21.0, 95 % CI: 19.8-22.4 vs. 5.0, 95 %
CI: 4.9-5.2) and HIV co-infection (ORs: 7.2, 95 % CI: 7.1-
8.9 vs. 4.8, 95 % CI: 4.5-5.2) were much higher for new in-
fections than for prevalent HCV infections. In a model
with age at diagnosis instead of birth cohort (Additional
file 1: Table S5), odds of prevalent infection were highest
among ages 45-54 years (OR: 4.0; 95 % CI: 3.9-4.2)
followed by 35-44 years (OR: 3.2; 95 % CI: 3.0-3.3) while
odds for new infection were highest among ages 15-24
years (OR: 11.4, 95 % CI: 9.0-14.4) and 25-34 years (OR:
11.1, 95 % CI: 8.8-14.0) and declined thereafter. Similar
results were observed using indicators for recent risk ac-
tivities (Additional file 1: Table S6).
Discussion
We used a large cohort of more than one million people
tested for HCV in BC, and while accounting for mortal-
ity, we found that a large number of people are currently
living with HCV. The highest positivity rate was among
people born in 1945-64, which declined over time and
was lowest in 2013. New infections were detected mainly
among younger age groups. The new HCV infection
(seroconversion) rate was highest among males, those
with HIV or HBV co-infection, mental health conditions,
problematic alcohol or illicit drug use, and socioeco-
nomically disadvantaged persons. Prevalent HCV infec-
tion was associated with being male, born 1945-64, HIV
co-infected, problem alcohol and illicit drug use, and
socioeconomic deprivation. These findings of twin epi-
demics highlight important opportunities for prevention,
testing and treatment of HCV.
In this analysis, we identified two groups of HCV in-
fected individuals: new infections (seroconverters) and
those with prevalent HCV infection. Most of those with
prevalent HCV were born 1945-1964, while most newly
infected individuals were younger. However, the sero-
converters are not a homogeneous group: 24-month ser-
oconverters differed from >24 months seroconverters in
terms of age, sex, testing patterns, and HBV co-infection
rate. Surveillance data on acute HCV infections indicate
that 70 % of seroconverters reported injection drug use
in the past 12 months [18]. In a BC-HTC subset for
whom self-reported risk factor data was available, 85 %
of those who self-reported injection drug use had a med-
ical visit for illicit drug use. Thus, 24-month seroconver-
ters most likely acquired HCV through their injection
drug use networks.
Most of the HCV cases, especially prevalent infections,
were identified among those born 1945-64 and the posi-
tivity rate was much higher in this group, especially for
those born 1950-1960. Similarly high 1945-64 birth co-
hort positivity rates have been reported in various stud-
ies from the United States [19–22]. Using reported HCV
cases in Canada, Trubnikov et al. found the highest
HCV prevalence among the 1950-54 and 1955-59 birth
cohorts, followed by 1960-64 and 1966-69, while preva-
lence among those born 1945-49 was lower than for
those born 1965-69 [2]. In contrast, in our study, the
positivity rate for birth cohort 1945-49 was higher than
for birth cohort 1965-69 (Fig. 2). Our findings are also
consistent with a study which assessed HCV related hos-
pital admissions where the 1950-54 and 1955-59 birth
cohorts had the highest rates [23]. Although the posi-
tivity rate is still highest among the 1945-64 birth co-
hort, the rate in this cohort has been declining over
successive years suggesting a decreasing pool of un-
diagnosed prevalent HCV infections. Canada has had
risk based testing guidelines since 1994 [24]. The de-
clining positivity rate in this birth cohort suggests
that testing driven by risk based guidelines have been
able to identify most people with current or past risk
activities and diagnose most of the HCV infections in
this cohort. However, risk based testing may not
identify individuals who are unable to recall or are
unwilling to disclose remote risk behaviors. The US
Preventive Services Task Force has recommended one
time testing of individuals born 1945-65 [22]. Further
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Table 3 Characteristics of currently alive HCV testers by HCV status and birth cohort, Canada, BC-HTC, 1990-2013
HCV Positive HCV Negative
<1945 1945-1964 1965-1974 ≥1975 <1945 1945-1964 1965-1974 ≥1975
N = 3168 N = 33946 N = 11883 N = 6784 N = 95848 N = 310845 N = 209956 N = 371732
N (%) N (%) N(%) N (%) N (%) N(%) N (%) N (%)
Age at baselinea
< 15 0 0 0 438 (6.5) 0 0 0 20289 (5.5)
15-24 0 0 857 (7.2) 2925 (43.1) 0 0 3591 (1.7) 141735 (38.1)
25-34 0 2764 (8.1) 6688 (56.3) 3166 (46.7) 0 6369 (2.1) 66420 (31.6) 186558 (50.2)
35-44 0 14198 (41.8) 4014 (33.8) 255 (3.8) 0 73286 (23.6) 124190 (59.2) 23150 (6.2)
45-54 425 (13.4) 13116 (38.6) 324 (2.7) 0 3166 (3.3) 144213 (46.4) 15755 (7.5) 0
≥ 55 2743 (86.6) 3868 (11.4) 0 0 92682 (96.7) 86977 (28.0) 0 0
Median [IQR] 63 [58-70] 45 [39-50] 32 [28-37] 25 [21–29] 69 [63-75] 50 [44-55] 37 [33-41] 26 [21–30]
Age at 1st test
< 15 0 0 0 605 (8.9) 0 0 0 25860 (7)
15-24 0 0 1205 (10.1) 3830 (56.5) 0 0 7867 (3.8) 181880 (48.9)
25-34 0 3074 (9.1) 7174 (60.4) 2182 (32.2) 0 12382 (4.0) 96703 (46.1) 151971 (40.9)
35-44 0 14485 (42.7) 3255 (27.4) 167 (2.5) 0 99462 (32.0) 96915 (46.2) 12021 (3.2)
45-54 436 (13.8) 12742 (37.5) 249 (2.1) 0 5217 (5.4) 134000 (43.1) 8471 (4.0) 0
≥ 55 2732 (86.2) 3645 (10.7) 0 0 90631 (94.6) 65001 (20.9) 0 0
Median [IQR] 63 [58-69] 44 [39-50] 31 [27-36] 22 [18–27] 67 [61-73] 48 [42-53] 35 [30-39] 24 [20–28]
Sex
Female 1354 (42.7) 10946 (32.3) 4288 (36.1) 3261 (48.1) 51063 (53.3) 164778 (53.0) 116339 (55.4) 219772 (59.1)
Male 1809 (57.1) 23000 (67.8) 7594 (63.9) 3523 (51.9) 44657 (46.6) 146061 (47.0) 93615 (44.6) 151954 (40.9)
Unknown 5 (0.2) 0 0 0 128 (0.1) 6 (0.0) 2 (0.0) 6 (0.0)
Year of diagnosis
1990-1994 340 (10.7) 2938 (8.7) 690 (5.8) 99 (1.5) 822 (0.9) 1858 (0.6) 889 (0.4) 344 (0.1)
1995-1999 1186 (37.4) 12980 (38.2) 3992 (33.6) 857 (12.6) 21815 (22.8) 48746 (15.7) 21003 (10.0) 13299 (3.6)
2000-2004 703 (22.2) 8333 (24.6) 3163 (26.6) 1650 (24.3) 19159 (20.0) 68035 (21.9) 43673 (20.8) 42021 (11.3)
2005-2009 555 (17.5) 6004 (17.7) 2588 (21.8) 2257 (33.3) 22709 (23.7) 81513 (26.2) 63756 (30.4) 104908 (28.2)
2010-2013 384 (12.1) 3691 (10.9) 1450 (12.2) 1921 (28.3) 31343 (32.7) 110693 (35.6) 80635 (38.4) 211160 (56.8)
HIV/AIDS at baseline
No/Unknown 3149 (99.4) 33150 (97.7) 11364 (95.6) 6562 (96.7) 95664 (99.8) 308950 (99.4) 208736 (99.4) 370832 (99.8)













Table 3 Characteristics of currently alive HCV testers by HCV status and birth cohort, Canada, BC-HTC, 1990-2013 (Continued)
HIV/AIDS co-infection (ever)
No/Unknown 3135 (99.0) 32345 (95.3) 10810 (91.0) 6335 (93.4) 95640 (99.8) 308728 (99.3) 208587 (99.4) 370739 (99.7)
Yes 33 (1.0) 1601 (4.7) 1073 (9.0) 449 (6.6) 208 (0.2) 2117 (0.7) 1369 (0.7) 993 (0.3)
HBV at baseline
No/Unknown 3130 (98.8) 33529 (98.8) 11686 (98.3) 6729 (99.2) 94660 (98.8) 304567 (98.0) 206304 (98.3) 368692 (99.2)
Yes 38 (1.2) 417 (1.2) 197 (1.7) 55 (0.8) 1188 (1.2) 6278 (2.0) 3652 (1.7) 3040 (0.8)
HBV co-infection (ever)
No/Unknown 3075 (97.1) 32643 (96.2) 11330 (95.4) 6658 (98.1) 94059 (98.1) 302130 (97.2) 204856 (97.6) 367414 (98.8)
Yes 93 (2.9) 1303 (3.8) 553 (4.7) 126 (1.9) 1789 (1.9) 8715 (2.8) 5100 (2.4) 4318 (1.2)
Active TB at baseline
No/Unknown 3157 (99.7) 33890 (99.8) 11863 (99.8) 6773 (99.8) 95584 (99.7) 310307 (99.8) 209650 (99.9) 371368 (99.9)
Yes 11 (0.4) 56 (0.2) 20 (0.2) 11 (0.2) 264 (0.3) 538 (0.2) 306 (0.2) 364 (0.1)
Active TB co-infection (ever)
No/Unknown 3149 (99.4) 33783 (99.5) 11808 (99.4) 6752 (99.5) 95494 (99.6) 310145 (99.8) 209558 (99.8) 371276 (99.9)
Yes 19 (0.6) 163 (0.5) 75 (0.6) 32 (0.5) 354 (0.4) 700 (0.2) 398 (0.2) 456 (0.1)
Material deprivation quintile at baseline
Unknown 106 (3.4) 1298 (3.8) 618 (5.2) 469 (6.9) 1199 (1.3) 3720 (1.2) 2671 (1.3) 7183 (1.9)
Q1 (most privileged) 507 (16.0) 4444 (13.1) 1362 (11.5) 830 (12.2) 18845 (19.7) 65327 (21.0) 48322 (23.0) 81513 (21.9)
Q2 513 (16.2) 5404 (15.9) 1636 (13.8) 936 (13.8) 18165 (19.0) 60803 (19.6) 39355 (18.7) 69264 (18.6)
Q3 533 (16.8) 6114 (18) 1926 (16.2) 1065 (15.7) 19060 (19.9) 61814 (19.9) 40022 (19.1) 71369 (19.2)
Q4 660 (20.8) 7365 (21.7) 2691 (22.7) 1514 (22.3) 20032 (20.9) 61824 (19.9) 40792 (19.4) 74468 (20.0)
Q5 (most deprived) 849 (26.8) 9321 (27.5) 3650 (30.7) 1970 (29.0) 18547 (19.4) 57357 (18.5) 38794 (18.5) 67935 (18.3)
Social deprivation quintile at baseline
Unknown 106 (3.4) 1298 (3.8) 618 (5.2) 469 (6.9) 1199 (1.3) 3720 (1.2) 2671 (1.3) 7183 (1.9)
Q1 (most privileged) 557 (17.6) 3477 (10.2) 1081 (9.1) 741 (10.9) 17348 (18.1) 57695 (18.6) 36550 (17.4) 68621 (18.5)
Q2 513 (16.2) 4335 (12.8) 1238 (10.4) 794 (11.7) 17802 (18.6) 56839 (18.3) 36109 (17.2) 64348 (17.3)
Q3 516 (16.3) 5802 (17.1) 1790 (15.1) 989 (14.6) 17342 (18.1) 56864 (18.3) 36204 (17.2) 65305 (17.6)
Q4 606 (19.1) 7152 (21.1) 2380 (20.0) 1257 (18.5) 19201 (20.0) 62437 (20.1) 42960 (20.5) 76953 (20.7)
Q5 (most deprived) 870 (27.5) 11882 (35.0) 4776 (40.2) 2534 (37.4) 22956 (24.0) 73290 (23.6) 55462 (26.4) 89322 (24.0)
Mental illness at baselineb
No/Unknown 2768 (89.8) 28051 (85.0) 9468 (81.9) 4942 (79.5) 75892 (90.3) 230429 (85.6) 160387 (87.7) 262690 (89.8)













Table 3 Characteristics of currently alive HCV testers by HCV status and birth cohort, Canada, BC-HTC, 1990-2013 (Continued)
Mental illness 3yr pre- baselineb
No/Unknown 2908 (94.3) 30114 (91.2) 10261 (88.8) 5478 (88.1) 80387 (95.7) 251001 (93.3) 172141 (94.2) 277513 (94.8)
Yes 176 (5.7) 2893 (8.8) 1294 (11.2) 741 (11.9) 3635 (4.3) 18064 (6.7) 10643 (5.8) 15068 (5.2)
Illicit drug use at baselineb
No/Unknown 2763 (89.6) 22649 (68.6) 6220 (53.8) 3256 (52.4) 81535 (97.0) 249677 (92.8) 167729 (91.8) 271558 (92.8)
Yes 321 (10.4) 10358 (31.4) 5335 (46.2) 2963 (47.6) 2487 (3.0) 19388 (7.2) 15055 (8.2) 21023 (7.2)
Illicit drug use 3yr pre- baselineb
No/Unknown 2870 (93.1) 25193 (76.3) 7090 (61.4) 3557 (57.2) 83133 (98.9) 259681 (96.5) 174045 (95.2) 278466 (95.2)
Yes 214 (6.9) 7814 (23.7) 4465 (38.6) 2662 (42.8) 889 (1.1) 9384 (3.5) 8739 (4.8) 14115 (4.8)
Problematic alcohol use at baselineb
No/Unknown 2724 (88.3) 25720 (77.9) 8780 (76.0) 4933 (79.3) 79838 (95.0) 248826 (92.5) 171200 (93.7) 277407 (94.8)
Yes 360 (11.7) 7287 (22.1) 2775 (24.0) 1286 (20.7) 4184 (5.0) 20239 (7.5) 11584 (6.3) 15174 (5.2)
Problematic alcohol use 3yr pre-baselineb
No/Unknown 2870 (93.1) 28620 (86.7) 9874 (85.5) 5421 (87.2) 81897 (97.5) 258911 (96.2) 177020 (96.8) 284664 (97.3)
Yes 214 (6.9) 4387 (13.3) 1681 (14.5) 798 (12.8) 2125 (2.5) 10154 (3.8) 5764 (3.2) 7917 (2.7)
aBaseline is defined as date of diagnosis (i.e. first HCV positive test or case report) for HCV positive individuals, and date of last negative test result for HCV negative individuals













studies on feasibility and cost effectiveness of various
strategies are needed to identify undiagnosed infec-
tions in BC.
Risk factors for both new and prevalent HCV infec-
tions were similar with some notable exceptions, includ-
ing age, birth cohort, drug use, HBV co-infection and
mental health diagnoses. HBV co-infection and mental
health problems were significantly associated with in-
creased odds of new infection but decreased odds of
prevalent HCV infection, while ORs for illicit drug use
compared to no drug use among new infections (AOR =
21) were four times than those for prevalent HCV infec-
tion (AOR = 5.0). ORs for prevalent HCV infection were
highest for birth cohort 1945-64 and declined thereafter,
while among new infections, ORs were highest for those
born later, consistent with an earlier analysis demon-
strating a higher HCV incidence rate in younger birth
cohorts [25]. Demographic characteristics and risk fac-
tors for prevalent HCV were also consistent with recent
data from the United States and Canada [8, 20]. Like-
wise, in a recent electronic medical record based study
from the US, being a baby boomer, male, people who
injects drugs (PWID), HIV co-infected and having low
income were associated with HCV positivity [26]. Risk
factors among new infections were also similar to those
identified with HCV infection in high risk populations,
mainly PWID. Among seroconverters especially 24-
months seroconverters, those born 1965-84, HIV/HBV
co-infection, socioeconomic deprivation, mental illness,
illicit drug use and problematic alcohol use were more
common than among prevalent HCV infections (Table 1/
Fig. 1). These findings highlight the presence of syndemics
of blood-borne infections (BBI), mental illness, addiction,
and socioeconomic marginalization in this population as
has been reported by others [27–29]. Addressing these
syndemics requires comprehensive services including inte-
grated testing, prevention and treatment for STI/BBIs, as
well as mental health and addiction services to address the
needs of this population group.
Findings from this paper should be interpreted in
the context of some methodological issues. The valid-
ity of our estimates depends on the successful linkage
rate. Linkage rates were very high for HCV (>85 %),
especially in recent years [14]. Linkage rates for those
HIV co-infected were much higher than the overall
HIV linkage rate, especially before 2005. Thus, the
HIV co-infection rate may have been underestimated.
However, as reported earlier, we used multiple sources
of HIV status identification to reduce underestima-
tion. In this study, we did not have access to immi-
gration and Aboriginal status data and hence we were
not able to characterize the disease burden among
immigrants and Aboriginal populations. Other data
suggest that Aboriginal people are five times more
likely to be infected with HCV [30]. Immigrants from
endemic countries are also more likely to have higher
HCV infection rates.
Table 4 Multivariable multinomial logistic regression models for
factors associated with seroconversion and prevalent HCV
infection in BC-HTC, Canada 1990-2012a, b
Variables Seroconverters Prevalent HCV
ORs (95 % CI) ORs (95 % CI)
Sex
Female 1.00 1.00
Male 1.25 (1.19-1.31) 2.06 (2.02-2.10)
Birth year
< 1945 1.00 1.00
1945-1954 3.38 (2.78-4.11) 3.79 (3.67-3.92)
1955-1964 6.22 (5.19-7.44) 3.23 (3.13-3.34)
1965-1974 9.86 (8.26-11.78) 1.64 (1.58-1.70)
1975-1984 11.76 (9.83-14.07) 0.70 (0.67-0.73)
≥ 1985 6.53 (5.34-7.99) 0.48 (0.44-0.51)
HIV infection at baselinec
No/Unknown 1.00 1.00
Yes 7.92 (7.05-8.89) 4.80 (4.47-5.15)
HBV at baselinec
No/Unknown 1.00 1.00
Yes 2.33 (2.00-2.71) 0.69 (0.63-0.75)
Active TB at baselinec
No/Unknown 1.00 1.00
Yes 1.00 (0.62-1.62) 1.01 (0.81-1.25)
Material deprivation quintile at
baselinec
Unknown 3.51 (2.96-4.17) 5.38 (5.07-5.70)
Q1 (most privileged) 1.00 1.00
Q2 1.20 (1.06-1.31) 1.22 (1.18-1.27)
Q3 1.24 (1.13-1.36) 1.36 (1.32-1.41)
Q4 1.62 (1.48-1.76) 1.60 (1.55-1.65)
Q5 (most deprived) 1.99 (1.83-2.15) 1.98 (1.92-2.04)
Mental illness at baselinec
No/Unknown 1.00 1.00
Yes 1.18 (1.12-1.25) 0.69 (0.67-0.72)
Illicit drugs use at baseline
No/Unknown 1.00 1.00
Yes 21.00 (19.80-22.38) 5.03 (4.91-5.16)
Problematic alcohol use at
baseline
No/Unknown 1.00 1.00
Yes 2.11 (2.00-2.23) 1.67 (1.63-1.72)
aAdjusted for health authority and year of diagnosis; bExcluding unknown
gender and health authority. cBaseline is defined as time of diagnosis for HCV
positive, and date of last negative for HCV negative
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To date, laboratory testing for HCV has followed risk
based guidelines and hence a higher positivity rate
among HCV testers in this cohort is expected compared
to the general population. However, general population
surveys such as the Canadian Health Measures Survey
may not capture high risk populations with higher HCV
prevalence thus and may underestimate total population
of infected individuals [8, 20]. Categorizing prevalent
infections based on being positive at the first test may be
an over-estimate as some of these individuals are likely
to be recent seroconverters as shown in our recent mo-
lecular analysis [31]. The prevalent HCV case detection
could be affected by presence of late stage symptomatic
disease or survival. Survival may also affect the differ-
ence in risk factor profile between prevalent and new
cases. In the BC-HTC, data is available on all cohort
members many years before cohort initiation to assess
risk factors as presented in Table 1. Thus, for all cohort
members regardless of first test or diagnosis date, data
on risk factors started at the same time, providing ample
time to assess risk factors from the available data. Fur-
thermore, after accounting for mortality in the cohort,
there was no difference in identified risk factor patterns
in models including both currently alive and dead and
only those currently who are currently alive. Thus, sur-
vival bias is unlikely to explain difference in risk factor
profile between prevalent and new infections. However,
survival bias is not expected to be completely eliminated
especially in early nineties, when people could have died
before HCV diagnosis or getting diagnosed because of
symptoms related to late stage disease. In another ana-
lysis, we found that late HCV diagnosis in relation to
advance stage liver disease (hepatocellular carcinoma
and decompensated cirrhosis) was common in early
nineties and have declined substantially over time [32].
In the current paper, data on RNA testing and active
infection was not presented, which is important to assess
people living with active infection and need treatment to
prevent progressive liver disease. The BC-HTC provides
a platform to assess program progress through cascade
of care monitoring, long term outcomes related to HCV
and impact of treatment on long term outcomes. These
data are in the process of being analyzed and will be pre-
sented in future reports.
Conclusions
The HCV positivity rate was highest in the 1950-54 and
1955-59 birth cohorts and overall among those born
between 1945- 1964, which declined over time. Further-
more, the year over year decline in the positivity rate
suggests that most of the HCV infections in these co-
horts have already been identified. However, current risk
based testing may not identify individuals who are un-
able to recall or are unwilling to disclose remote risk
behaviors. Further studies are needed to estimate the
number of undiagnosed HCV infection and assess opti-
mal strategies to identify the remaining undiagnosed in-
fections. Newly acquired infections are occurring mainly
in younger birth cohorts and these groups are more
likely to be co-infected with HIV and/or HBV, socioeco-
nomically marginalized, and living with serious mental
illnesses and addictions. Comprehensive syndemic ap-
proaches that take into account co-infections, mental
health, additions and socioeconomic vulnerabilities are
urgently required to identify, treat, and support people
with HCV infection.
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